MCID: ACT073
MIFTS: 58

Acute Leukemia

Categories: Blood diseases, Bone diseases, Cancer diseases, Immune diseases

Aliases & Classifications for Acute Leukemia

MalaCards integrated aliases for Acute Leukemia:

Name: Acute Leukemia 12 29 54 15 37 17 71
Acute Undifferentiated Leukemia 71
Undifferentiated Leukemia 71
Stem Cell Leukaemia 12
Stem Cell Leukemia 12
Acute Leukemias 15

Classifications:



External Ids:

Disease Ontology 12 DOID:12603
ICD9CM 34 208.0
NCIt 49 C9300
SNOMED-CT 67 24072005 91855006
ICD10 32 C95.0 C95.00
UMLS 71 C0085669 C0280141 C1378511

Summaries for Acute Leukemia

Disease Ontology : 12 A leukemia that occurs when a hematopoietic stem cell undergoes malignant transformation into a primitive, undifferentiated cell with abnormal longevity. These lymphocytes (acute lymphocytic leukemia [ALL]) or myeloid cells (acute myelocytic leukemia [AML]) proliferate abnormally, replacing normal marrow tissue and hematopoietic cells and inducing anemia, thrombocytopenia, and granulocytopenia.

MalaCards based summary : Acute Leukemia, also known as acute undifferentiated leukemia, is related to acute promyelocytic leukemia and chronic leukemia. An important gene associated with Acute Leukemia is WT1 (WT1 Transcription Factor), and among its related pathways/superpathways are Endometrial cancer and Pathways in cancer. The drugs Arsenic trioxide and Micafungin have been mentioned in the context of this disorder. Affiliated tissues include myeloid, bone and bone marrow, and related phenotypes are hematopoietic system and immune system

Wikipedia : 74 Acute leukemia or acute leukaemia is a family of serious medical conditions relating to an original... more...

Related Diseases for Acute Leukemia

Diseases in the Leukemia family:

Chronic Leukemia Acute Leukemia
Subacute Leukemia

Diseases related to Acute Leukemia via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 837)
# Related Disease Score Top Affiliating Genes
1 acute promyelocytic leukemia 33.2 WT1 RUNX1 MPO KMT2A FLT3 ETV6
2 chronic leukemia 33.1 WT1 KIT JAK2 FLT3
3 megakaryocytic leukemia 33.1 RUNX1 MPO KMT2A JAK2
4 myelodysplastic/myeloproliferative neoplasm 33.1 KMT2A JAK2 FLT3 ETV6
5 severe congenital neutropenia 32.9 MPO JAK2 FLT3 CSF3
6 lymphoblastic lymphoma 32.9 PAX5 MPO KMT2A DNTT
7 childhood leukemia 32.8 RUNX1 MTHFR MPO MLLT3 KMT2A ETV6
8 leukemia, acute myeloid 32.6 WT1 RUNX1 PAX5 MPO MLLT3 KMT2A
9 leukemia 32.5 WT1 STMN1 RUNX1 PAX5 MTHFR MLLT3
10 myeloproliferative neoplasm 32.3 WT1 RUNX1 MPO KMT2A KIT JAK2
11 lymphocytic leukemia 32.2 RUNX1 PAX5 KMT2A ETV6 DNTT ANPEP
12 leukemia, acute lymphoblastic 32.0 WT1 RUNX1 PAX5 MTHFR MPO MLLT3
13 myelodysplastic syndrome 31.8 WT1 RUNX1 MPO KMT2A KIT JAK2
14 childhood acute lymphocytic leukemia 31.5 MTHFR ETV6 AFF1
15 precursor t-cell acute lymphoblastic leukemia 31.4 MPO KMT2A FLT3 ETV6 DNTT ANPEP
16 acute myeloblastic leukemia with maturation 31.4 KIT FLT3
17 monocytic leukemia 31.3 RUNX1 MPO MLLT3 KMT2A FLT3
18 aplastic anemia 31.3 WT1 MPO GSTM1 FLT3 CSF3
19 thrombocytopenia 31.3 RUNX1 PAX5 JAK2 ETV6 CSF3
20 myeloma, multiple 31.2 PAX5 KIT JAK2 FLT3 CSF3
21 myeloid leukemia 31.2 WT1 RUNX1 MPO KMT2A KIT JAK2
22 deficiency anemia 31.2 JAK2 GSTM1 FLT3 CSF3 ANPEP
23 down syndrome 31.2 RUNX1 MTHFR JAK2 ETV6
24 polycythemia vera 31.2 KIT JAK2 ETV6 CSF3
25 pancytopenia 31.1 RUNX1 MPO KMT2A KIT CSF3 ANPEP
26 refractory anemia 31.1 RUNX1 CSF3
27 exanthem 31.0 KIT FLT3 CSF3
28 leukemia, acute lymphoblastic 3 31.0 RUNX1 PAX5 MPO KMT2A FLT3 ETV6
29 chronic myelomonocytic leukemia 30.9 RUNX1 KIT JAK2 FLT3 ETV6 CSF3
30 acute erythroid leukemia 30.9 JAK2 CEBPA
31 leukemia, acute monocytic 30.9 MPO MLLT3 KMT2A FLT3 CREBBP ANPEP
32 lymphoma, non-hodgkin, familial 30.8 PAX5 KMT2A JAK2 FLT3 ETV6 DNTT
33 essential thrombocythemia 30.8 MTHFR MPO KIT JAK2 CSF3
34 myelofibrosis 30.8 WT1 RUNX1 MPO KIT JAK2 FLT3
35 wilms tumor 1 30.8 WT1 KMT2A KIT FLT3 CEBPA
36 leukemia, chronic lymphocytic 30.8 PAX5 KMT2A KIT JAK2 FLT3 DNTT
37 acute myeloid leukemia with abnormal bone marrow eosinophils inv(16)(p13q22) or t(16;16)(p13;q22) 30.8 RUNX1 MPO KMT2A KIT FLT3 ETV6
38 myeloid sarcoma 30.6 PAX5 MPO KMT2A KIT FLT3 DNTT
39 mastocytosis 30.6 KIT JAK2 FLT3
40 leukemia, chronic myeloid 30.5 WT1 RUNX1 MPO KMT2A KIT JAK2
41 blood coagulation disease 30.4 MTHFR KIT JAK2 CSF3
42 chronic eosinophilic leukemia 30.4 WT1 KIT JAK2 FLT3 ETV6
43 tetrasomy 21 30.4 RUNX1 DNTT ANPEP
44 acute myeloid leukemia with minimal differentiation 30.3 MPO FLT3
45 8p11 myeloproliferative syndrome 30.3 RUNX1 KIT FLT3
46 precursor b lymphoblastic lymphoma/leukemia 30.3 PAX5 DNTT ANPEP
47 nondisjunction 30.3 MTHFR KIT
48 juvenile myelomonocytic leukemia 30.3 RUNX1 KMT2A JAK2 FLT3 CREBBP
49 cytogenetically normal acute myeloid leukemia 30.3 WT1 KMT2A FLT3 CEBPA
50 atypical chronic myeloid leukemia 30.3 RUNX1 JAK2 ETV6

Comorbidity relations with Acute Leukemia via Phenotypic Disease Network (PDN):


Deficiency Anemia Neutropenia

Graphical network of the top 20 diseases related to Acute Leukemia:



Diseases related to Acute Leukemia

Symptoms & Phenotypes for Acute Leukemia

MGI Mouse Phenotypes related to Acute Leukemia:

45 (show all 14)
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 10.4 AFF1 ANPEP CEBPA CREBBP CSF3 DNTT
2 immune system MP:0005387 10.36 AFF1 ANPEP CEBPA CREBBP CSF3 DNTT
3 homeostasis/metabolism MP:0005376 10.35 CEBPA CREBBP DNTT ETV6 FLT3 JAK2
4 growth/size/body region MP:0005378 10.32 AFF1 CEBPA CREBBP ETV6 FLT3 JAK2
5 cardiovascular system MP:0005385 10.31 ANPEP CEBPA CREBBP ETV6 JAK2 KIT
6 endocrine/exocrine gland MP:0005379 10.22 AFF1 ANPEP CEBPA CREBBP ETV6 FLT3
7 mortality/aging MP:0010768 10.21 AFF1 CEBPA CREBBP ETV6 FLT3 JAK2
8 integument MP:0010771 10.13 ANPEP CEBPA CREBBP CSF3 ETV6 JAK2
9 liver/biliary system MP:0005370 10.01 CEBPA CREBBP JAK2 KIT KMT2A MTHFR
10 neoplasm MP:0002006 10 CEBPA CREBBP ETV6 FLT3 JAK2 KIT
11 muscle MP:0005369 9.92 CEBPA CREBBP KIT KMT2A MPO PAX5
12 no phenotypic analysis MP:0003012 9.85 AFF1 CEBPA ETV6 FLT3 KIT KMT2A
13 normal MP:0002873 9.7 CEBPA CREBBP DNTT ETV6 JAK2 KIT
14 skeleton MP:0005390 9.28 CREBBP FLT3 JAK2 KIT KMT2A MLLT3

Drugs & Therapeutics for Acute Leukemia

Drugs for Acute Leukemia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 453)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Arsenic trioxide Approved, Investigational Phase 4 1327-53-3 518740
2
Micafungin Approved, Investigational Phase 4 235114-32-6 3081921 477468
3
Cefepime Approved, Investigational Phase 4 88040-23-7 5479537
4
Ceftazidime Approved Phase 4 72558-82-8, 78439-06-2 5481173
5
Etoposide Approved Phase 4 33419-42-0 36462
6
Daunorubicin Approved Phase 4 20830-81-3 30323
7
Mercaptopurine Approved Phase 4 50-44-2 667490
8
Vincristine Approved, Investigational Phase 4 2068-78-2, 57-22-7 5978
9
Prednisone Approved, Vet_approved Phase 4 53-03-2 5865
10
Lenograstim Approved, Investigational Phase 4 135968-09-1
11
Amphotericin B Approved, Investigational Phase 4 1397-89-3 14956 5280965
12
Sargramostim Approved, Investigational Phase 4 123774-72-1, 83869-56-1
13 Anti-Inflammatory Agents Phase 4
14 glucocorticoids Phase 4
15 Antimitotic Agents Phase 4
16 Etoposide phosphate Phase 4
17 Cyclosporins Phase 4
18 Hormone Antagonists Phase 4
19 Hormones Phase 4
20 Mitogens Phase 4
21 Antiparasitic Agents Phase 4
22 Liposomal amphotericin B Phase 4
23 Antiprotozoal Agents Phase 4
24 Cytochrome P-450 CYP3A Inhibitors Phase 4
25 Cytochrome P-450 Enzyme Inhibitors Phase 4
26 Steroid Synthesis Inhibitors Phase 4
27 Adjuvants, Immunologic Phase 4
28 Cytochrome P-450 CYP2C9 Inhibitors Phase 4
29
Ketamine Approved, Vet_approved Phase 3 6740-88-1 3821
30
Vindesine Approved, Investigational Phase 3 53643-48-4, 59917-39-4 40839
31
Oprelvekin Approved, Investigational Phase 2, Phase 3 145941-26-0
32
Thiotepa Approved, Investigational Phase 3 52-24-4 5453
33
Aldesleukin Approved Phase 3 110942-02-4, 85898-30-2
34 Clove Approved Phase 2, Phase 3
35
Dalteparin Approved Phase 3 9005-49-6
36
Dextromethorphan Approved Phase 3 125-71-3 5360696 5362449
37
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
38
Levofloxacin Approved, Investigational Phase 3 100986-85-4 149096
39
Ofloxacin Approved Phase 3 82419-36-1 4583
40
Darbepoetin alfa Approved, Investigational Phase 3 209810-58-2, 11096-26-7
41
Pentostatin Approved, Investigational Phase 3 53910-25-1 40926 439693
42
Chlorambucil Approved Phase 3 305-03-3 2708
43
Adenosine Approved, Investigational Phase 3 58-61-7 60961
44
Bleomycin Approved, Investigational Phase 3 11056-06-7 5360373
45
Dacarbazine Approved, Investigational Phase 3 4342-03-4 5351166
46
Procarbazine Approved, Investigational Phase 3 671-16-9 4915
47
Vinblastine Approved Phase 3 865-21-4 13342 241903
48
inotuzumab ozogamicin Approved, Investigational Phase 3 635715-01-4
49
Irinotecan Approved, Investigational Phase 3 97682-44-5, 100286-90-6 60838
50
Rasburicase Approved, Investigational Phase 2, Phase 3 134774-45-1

Interventional clinical trials:

(show top 50) (show all 895)
# Name Status NCT ID Phase Drugs
1 Treatment Plan for Hematologic Malignancies Using Intravenous Busulfan and Cyclophosphamide Instead of Total Boby Irradiation (TBI) and Cyclophosphamide to Examine Results, Success and Side Effects of Treatment With Chemotherapy Only, as a Preparative Therapy for Patients With Cord Blood Transplants Unknown status NCT01339988 Phase 4 Busulfan/Cyclophosphamide
2 Treatment of Relapsed Acute Promyelocytic Leukemia With Arsenic Trioxide (Phase IV Study) Unknown status NCT00196768 Phase 4 Arsenic trioxide;Trisenox
3 A Randomized Open-Label Trial of Posaconazole Versus Micafungin for Prophylaxis Against Invasive Fungal Infections During Neutropenia in Patients Undergoing Chemotherapy for Acute Myelogenous Leukemia, Acute Lymphocytic Leukemia or Myelodysplastic Syndrome Completed NCT01200355 Phase 4 micafungin;posaconazole
4 A Phase IV Study of Corticosteroids As Prophylaxis for Infusion-Related Adverse Events to Mylotarg® in Patients With Acute Myelogenous Leukemia (AML) Completed NCT00304447 Phase 4 Mylotarg
5 Cefepime vs Ceftazidime as Empirical Therapy for Neutropenic Fever in Pediatric Acute Leukemia: Review of Temperature and Absolute Neutrophil Completed NCT04187755 Phase 4 Ceftazidime Injection;Cefepime Injection
6 AmBisome® in Combination With Caspofungin Versus AmBisome® High Dose Regimen for the Treatment of Invasive Aspergillosis in Immunocompromized Patients: Randomized Pilot Study. Completed NCT00334412 Phase 4 Ambisome;caspofungin
7 APL-R2007: Treatment of Relapsed Promyelocytic Leukemia With Arsenic Trioxide (ATO) Completed NCT00504764 Phase 4 Arsenic Trioxide;ATRA
8 Treatment With Thrombopoietin Mimetic Plus Immunosuppressive Therapy in Egyptian Patients With Aplastic Anaemia Recruiting NCT03896971 Phase 4 Combination of thrombopoietin mimetic and cyclosporin A
9 Pethema LAL-RI/2008: Treatment for Patients With Standard Risk Acute Recruiting NCT02036489 Phase 4 Vincristine;Daunorubicin;Prednisone;L-asparaginase;Ciclophosphamide;Metotrexate;ARA-C;Hidrocortisone;Mercaptopurine;VP-16;Dexametasone
10 Safety and Efficacy Study of Busulfan/FLAG Conditioning Regimen in Patients With Relapsed/Refractory Acute Leukemia Undergoing Allogeneic Peripheral Blood Stem Cell Transplantation Not yet recruiting NCT02784561 Phase 4 Busulfan (Zhejiang Otsuka Pharmaceutical Co. Ltd);Cytarabine(Actavis Italy S.p.A);Fludarabine (Bayer);granulocyte colony-stimulating factor (KirinKunpeng);rabbit ATG(Sanofi/Genzyme)
11 A Randomized,Open,Multicenter and Prospective Study of the Optimized Dose of Anti-Thymoglobuline in Haploidentical Allogeneic Stem Cell Transplantation Not yet recruiting NCT03190733 Phase 4 ATG
12 ProphyALL - Pilot Study on Safety of Four Weekly Administrations of 7 mg/kg of Liposomal Amphotericin B (AmBisome®) in Antifungal Primary Prophylaxis Treatment of Elderly Patients With Acute Lymphoblastic Leukemia Undergoing Induction Chemotherapy Within the GMALL-Elderly Protocol Terminated NCT00386997 Phase 4 liposomal amphotericin B (AmBisome®)
13 Subcutaneous (SC) vs. Intravenous (IV) Granulocyte Colony Stimulating Factors (G-CSF) for the Treatment of Neutropenia in Hospitalized Haemato-oncological Patients: Randomized Controlled Trial Terminated NCT01222819 Phase 4 filgrastim
14 Multicenter, Double-Blind, Randomized Study to Compare the Safety and Efficacy of Levofloxacin With That of Cefepime in the Treatment of Fever and Neutropenia - Phase IIIB Unknown status NCT00020865 Phase 3 cefepime hydrochloride;levofloxacin
15 A Randomized Double-Blind Controlled Trial of Ketamine Versus Placebo in Conjunction With Best Pain Management in Neuropathic Pain in Cancer Patients Unknown status NCT01316744 Phase 3 ketamine hydrochloride
16 The Value of Dexamethasone Versus Prednisolone During Induction and Maintenance Therapy of Prolonged Versus Conventional Duration of L-Asparaginase Therapy During Consolidation and Late Intensification, and of Corticosteroid + VCR Pulses During Maintenance in Acute Lymphoblastic Leukemia and Lymphoblastic Non-Hodgkin Lymphoma of Childhood Unknown status NCT00003728 Phase 3 asparaginase;cyclophosphamide;cytarabine;daunorubicin hydrochloride;dexamethasone;doxorubicin hydrochloride;etoposide;leucovorin calcium;mercaptopurine;methotrexate;methylprednisolone;mitoxantrone hydrochloride;prednisolone;therapeutic hydrocortisone;thioguanine;vincristine sulfate;vindesine
17 Minimal Residual Disease-directed Donor Lymphocyte Infusion for Reduce of Relapse After Allogenetic Hematopoietic Stem Cell Transplantation Unknown status NCT02673008 Phase 2, Phase 3
18 Oral Voriconazole vs IV Low Dose Amphotericin B for Primary Antifungal Prophylaxis in Pediatric Acute Leukemia Induction:A Prospective, Randomized, Clinical Trial. Unknown status NCT00624143 Phase 3 ORAL VORICONAZOLE and IV Amphotericin B
19 Decitabine Augments for Post Allogeneic Stem Cell Transplantation in Patients With Acute Myeloid Leukemia and Myelodysplastic Syndrome Unknown status NCT01809392 Phase 2, Phase 3 decitabine
20 Megakaryocytic Progenitor Cells for Prophylaxis and Treatment of Thrombocytopenia in Patients With Acute Leukemia Receiving Chemotherapy Unknown status NCT02241031 Phase 2, Phase 3 thrombopoietin (TPO) and interleukin-11
21 A Prospective, Multicenter Randomized Study Comparing Single Versus Double Umbilical Cord Blood Transplantation in Children and Young Adults (<35 Years) With Acute Leukemia Remission Unknown status NCT01067300 Phase 3
22 A Randomized Trial of Thymoglobulin to Prevent Chronic Graft Versus Host Disease in Patients Undergoing Hematopoietic Progenitor Cell Transplantation (HPCT) From Unrelated Donors Unknown status NCT01217723 Phase 3
23 Evaluation of Plasmatic Levels of Busulfan in Patients Undergoing Hematopoietic Stem Cell Transplantation Unknown status NCT01800643 Phase 2, Phase 3
24 A RANDOMIZED TRIAL OF UNMODIFIED VERSUS T-CELL DEPLETED ALLOGENEIC HLA-IDENTICAL BONE MARROW TRANSPLANTATION FOR THE TREATMENT OF ACUTE LEUKEMIAS Completed NCT00002534 Phase 3 cyclophosphamide;cytarabine;methylprednisolone;thiotepa
25 Allogeneic Blood or Marrow Transplantation for Hematologic Malignancy and Aplastic Anemia Completed NCT00003816 Phase 2, Phase 3 busulfan;carboplatin;cyclophosphamide;etoposide;fludarabine phosphate;melphalan;thiotepa
26 Clofarabine, Cyclophosfamide, And Etoposide For The Treatment Of Relapsed Or Resistant Acute Leukemia In Pediatric Patients Completed NCT01385891 Phase 2, Phase 3 Clofarabine VP 16 ciclophospahamide
27 A Multicenter, Double-Blind, Randomized, Comparative Study To Evaluate The Safety, Tolerability, And Efficacy Of MK-0991 Versus (Amphotericin B) Liposome For Injection As Empirical Therapy In Patients With Persistent Fever And Neutropenia Completed NCT00008359 Phase 3 caspofungin acetate;liposomal amphotericin B
28 Phase III, Randomized, Double-Blind, Placebo-Controlled Crossover Trial of Ondansetron in the Control of Chronic Nausea and Vomiting Not Due to Antineoplastic Therapy in Patients With Advanced Cancer Completed NCT00006348 Phase 3 ondansetron
29 A Phase III Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effects of Fragmin (5,000 IU Subcutaneously) in Preventing Catheter-Related Complications When Given Daily to Cancer Patients With Central Venous Catheters Completed NCT00006083 Phase 3 Fragmin
30 A Phase III Double-Blind Equivalence Study of Two Different Formulations of Slow-Release Morphine Followed by a Randomization Between Dextromethorphan or Placebo Plus Statex SR for Chronic Cancer Pain Relief in Terminally Ill Patients Completed NCT00003687 Phase 3 dextromethorphan hydrobromide;morphine sulfate
31 The Unrelated Donor Marrow Transplantation Trial Completed NCT00003187 Phase 2, Phase 3 cyclophosphamide;cyclosporine;cytarabine;methotrexate;methylprednisolone
32 A Randomized Trial of Levofloxacin to Prevent Bacteremia in Children Being Treated for Acute Leukemia (AL) or Undergoing Hematopoietic Stem Cell Transplantation (HSCT) Completed NCT01371656 Phase 3 levofloxacin
33 A Phase III, Randomized Study of the Effects of Parenteral Iron, Oral Iron, or No Iron Supplementation on the Erythropoietic Response to Darbepoetin Alfa for Cancer Patients With Chemotherapy-Associated Anemia Completed NCT00661999 Phase 3 sodium ferric gluconate complex in sucrose
34 A Phase III, Randomized, Multicentre Trial Comparing Allogeneic Filgrastim Mobilised Peripheral Blood Progenitor Cell Transplantation (PBPCT) With Allogeneic Bone Marrow Transplantation (BMT) in Patients With Acute Leukemia, Chronic Myelogenous Leukemia or Myelodysplastic Syndrome Completed NCT01020175 Phase 3
35 Preparatory Aid to Improve Decision Making About Cancer Clinical Trials (PRE-ACT) Completed NCT00750009 Phase 3
36 A Strategic Study to Determine the Optimal Moment to Initiate Systemic Antifungal Therapy With Ambisome in Granulocytopenic Cancer Patients With Unexplained Fever Refractory to Empirical Antibacterials Completed NCT00003938 Phase 3 liposomal amphotericin B
37 The Use of American Ginseng (Panax Quinquefolius) to Improve Cancer-Related Fatigue: A Randomized, Double-Blind, Placebo-Controlled Phase III Study Completed NCT00719563 Phase 3 American ginseng
38 Phase III Randomized Trial of an Opioid Titration Order Sheet Compared to Standard of Care in Patients With Cancer Related Pain. Completed NCT00666211 Phase 3
39 A Randomized, Double-blind, Placebo-controlled Multi-center Study to Evaluate the Safety and Efficacy of Fentanyl Sublingual Spray (Fentanyl SL Spray) for the Treatment of Breakthrough Cancer Pain Completed NCT00538850 Phase 3 Fentanyl sublingual spray;Placebo
40 A Phase III Randomized Study of Farnesyl Transferase Inhibitor R115777 in Acute Myeloid Leukemia (AML) Patients in Second or Subsequent Remission or in Remission After Primary Induction Failure or Patients Over Age 60 in First Remission Completed NCT00093470 Phase 3 Tipifarnib
41 Prophylaxis of Chronic Graft-versus-host Disease (cGvHD) With or Without Anti-T-lymphocyte-globulin (ATG Fresenius) Prior Allogeneic Peripheral Stem Cell Transplantation From HLA-identical Siblings After Myeloablative Conditioning in Patients With Acute Leukemia: A Randomized Phase III-study Completed NCT00678275 Phase 3 ATG FRESENIUS (Anti-Lymphocyte-Globulin);ATG FRESENIUS (Anti-Lymphocyte-Globulin)
42 A Phase III Study to Evaluate the Efficacy and Safety of Front-Line Therapy With Alemtuzumab (Campath, MabCampath) vs Chlorambucil in Patients With Progressive B-Cell Chronic Lymphocytic Leukemia Completed NCT00046683 Phase 3 alemtuzumab
43 Phase III Study of MDR Modulation With PSC-833 (NSC #648265) Followed by Immunotherapy With rIL-2 (NSC #373364) vs. No Further Therapy in Previously Untreated Patients With AML &gt;60 Years Completed NCT00003190 Phase 3 cytarabine;daunorubicin hydrochloride;etoposide;valspodar
44 A Randomized Study of Two Doses Gemtuzumab Ozogamicin vs. A Two-year Maintenance With Atra Plus Chemotherapy as Post-consolidation Treatment for Intermediate and High-risk Adult Patients With Acute Promyelocytic Leukemia (Apl) Completed NCT00962767 Phase 3 gemtuzumab ozogamicin;ATRA plus 6-MP and MTX
45 Phase III Randomized Study of Induction Chemotherapy With or Without MDR-Modulation With PSC-833 (NSC # 648265, IND # 41121) Followed by Cytogenetic Risk-Adapted Intensification Therapy Followed by Immunotherapy With rIL-2 (NSC # 373364, IND # 1969) vs. Observation in Previously Untreated Patients With AML &lt; 60 Years Completed NCT00006363 Phase 3 cytarabine;daunorubicin hydrochloride;etoposide;valspodar;busulfan
46 The Treatment of Down Syndrome Children With Acute Myeloid Leukemia (AML) and Myelodysplastic Syndromes (MDS) Under the Age of 4 Years Completed NCT00369317 Phase 3 asparaginase;daunorubicin hydrochloride;cytarabine;thioguanine;etoposide
47 Detection of Minimal Residual Disease in Newly Diagnosed Patients With Leukemia and Those Who Undergo a Bone Marrow Transplant Using the Wilms Tumor Suppressor Gene (WT1) as a Marker By RT-PCR Completed NCT00179829 Phase 2, Phase 3
48 Phase 3 Study of US-ATG-F to Prevent Moderate to Severe Chronic GVHD in Adult Acute Myeloid Leukemia, Acute Lymphoid Leukemia, and Myelodysplastic Syndrome Patients After Allogeneic Stem Cell Transplantation From Unrelated Donors Completed NCT01295710 Phase 3
49 Randomized Comparison of Once-daily Intravenous Busulfan Plus Cyclophosphamide Versus Fludarabine as a Conditioning Regimen for Allogeneic Hematopoietic Cell Transplantation in Leukemia and Myelodysplastic Syndrome Completed NCT00774280 Phase 3 BuCy vs BuFlu
50 A Randomized Phase 2/3 Study of DACOGEN® (Decitabine) Plus Talacotuzumab (JNJ-56022473; Anti CD123) Versus DACOGEN (Decitabine) Alone in Patients With AML Who Are Not Candidates for Intensive Chemotherapy Completed NCT02472145 Phase 2, Phase 3 Decitabine 20 mg/m^2;Talacotuzumab 9 mg/kg

Search NIH Clinical Center for Acute Leukemia

Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Acute Leukemia cell therapies at LifeMap Discovery.
Stem-cell-based therapeutic approaches for Acute Leukemia:
Promostem, mesenchymal stem cells for treatment of graft-versus-host disease

Genetic Tests for Acute Leukemia

Genetic tests related to Acute Leukemia:

# Genetic test Affiliating Genes
1 Acute Leukemia 29

Anatomical Context for Acute Leukemia

MalaCards organs/tissues related to Acute Leukemia:

40
Myeloid, Bone, Bone Marrow, T Cells, B Cells, Liver, Testes

Publications for Acute Leukemia

Articles related to Acute Leukemia:

(show top 50) (show all 16897)
# Title Authors PMID Year
1
Bench to bedside targeting of FLT3 in acute leukemia. 54 61
20370649 2010
2
Targeting CREB for cancer therapy: friend or foe. 54 61
20370681 2010
3
A role for PKR in hematologic malignancies. 54 61
20232306 2010
4
Clinical correlation of circulating heat shock protein 70 in acute leukemia. 54 61
19800118 2010
5
RUNX1/core binding factor A2 regulates platelet 12-lipoxygenase gene (ALOX12): studies in human RUNX1 haplodeficiency. 54 61
20181616 2010
6
Complex and cryptic chromosomal rearrangements involving the MLL gene in acute leukemia: a study of 7 patients and review of the literature. 54 61
20206559 2010
7
Functional characterization of high levels of meningioma 1 as collaborating oncogene in acute leukemia. 54 61
20072157 2010
8
The clinical characteristics of CD7+ CD56+ acute myeloid leukemias other than M0. 54 61
20111912 2010
9
[Expression of CREB/Bcl-2 in bone marrow mononuclear cells of children with acute leukemia]. 54 61
20350424 2010
10
Droplet-based gene expression analysis using a device with magnetic force-based-droplet-handling system. 54 61
20129107 2010
11
Retroviral insertional mutagenesis identifies Zeb2 activation as a novel leukemogenic collaborating event in CALM-AF10 transgenic mice. 54 61
20007546 2010
12
PCI-24781, a Novel Hydroxamic Acid HDAC Inhibitor, Exerts Cytotoxicity and Histone Alterations via Caspase-8 and FADD in Leukemia Cells. 54 61
20145726 2010
13
Cytochemically myeloperoxidase positive childhood acute leukemia with lymphoblastic morphology treated as lymphoblastic leukemia. 54 61
19935430 2010
14
Proleukemic RUNX1 and CBFbeta mutations in the pathogenesis of acute leukemia. 54 61
20306249 2010
15
[FLT3 gene mutation and its prognostic implication in patients with acute leukemia.]. 54 61
20302766 2010
16
[Clinical significance of detecting serum erythropoietin in patients with leukemia]. 54 61
19923094 2009
17
Discrepant immunophenotypic characteristics between the lymph node and bone marrow in two mixed-phenotype acute leukemia patients. 54 61
19893347 2009
18
PKR activity is required for acute leukemic cell maintenance and growth: a role for PKR-mediated phosphatase activity to regulate GSK-3 phosphorylation. 54 61
19507191 2009
19
Outcomes of CAG regimen for refractory biphenotypic acute leukemia patients. 54 61
19848320 2009
20
Rearrangements of the MLL gene are influenced by DNA secondary structure, potentially mediated by topoisomerase II binding. 54 61
19530238 2009
21
ABCB1 and ABCG2 proteins, their functional activity and gene expression in concert with drug sensitivity of leukemia cells. 54 61
19635183 2009
22
[Studies on the mutation and polymorphism of the TPMT gene in Chinese children with acute leukemia]. 54 61
20017316 2009
23
Wilms' tumor gene 1 expression analysis by real-time quantitative polymerase chain reaction for monitoring of minimal residual disease in acute leukemia. 54 61
19811333 2009
24
New insights to the MLL recombinome of acute leukemias. 54 61
19262598 2009
25
GATA-1 and GATA-2 binding to 3' enhancer of WT1 gene is essential for its transcription in acute leukemia and solid tumor cell lines. 54 61
19212333 2009
26
Clinical and biological characteristics of adult biphenotypic acute leukemia in comparison with that of acute myeloid leukemia and acute lymphoblastic leukemia: a case series of a Chinese population. 54 61
19454497 2009
27
Survivin mediates aberrant hematopoietic progenitor cell proliferation and acute leukemia in mice induced by internal tandem duplication of Flt3. 54 61
19411632 2009
28
Aberrant expression of TSC2 gene in the newly diagnosed acute leukemia. 54 61
19250671 2009
29
High frequency of RUNX1 biallelic alteration in acute myeloid leukemia secondary to familial platelet disorder. 54 61
19357396 2009
30
Detection of myeloperoxidase activity in primary leukemic cells by an enhanced chemiluminescent assay for differentiation between acute lymphoblastic and non-lymphoblastic leukemia. 54 61
19298796 2009
31
Panobinostat treatment depletes EZH2 and DNMT1 levels and enhances decitabine mediated de-repression of JunB and loss of survival of human acute leukemia cells. 54 61
19279403 2009
32
Overexpression of an isoform of AML1 in acute leukemia and its potential role in leukemogenesis. 54 61
19151769 2009
33
[IDA-FLAG regimen in treatment of patients with refractory or relapsed acute leukemia]. 54 61
19379589 2009
34
[Myeloproliferative diseases caused by JAK2 mutation]. 54 61
19489438 2009
35
Transforming activity of AML1-ETO is independent of CBFbeta and ETO interaction but requires formation of homo-oligomeric complexes. 54 61
19202074 2009
36
Small molecule XIAP inhibitors cooperate with TRAIL to induce apoptosis in childhood acute leukemia cells and overcome Bcl-2-mediated resistance. 54 61
19036706 2009
37
A retroviral mutagenesis screen reveals strong cooperation between Bcl11a overexpression and loss of the Nf1 tumor suppressor gene. 54 61
18948576 2009
38
The role of myeloid growth factors in acute leukemia. 54 61
19176208 2009
39
Expression of lineage markers using real-time quantitative polymerase chain reaction (RT-qPCR) in normal and in leukemia bone marrow. 54 61
19327122 2009
40
Maternal acute lymphoctic leukemia with rearrangement of the mixed lineage leukemia gene occurring during pregnancy. 54 61
20139053 2009
41
RAS, FLT3, and C-KIT mutations in immunophenotyped canine leukemias. 54 61
18977066 2009
42
Acute leukemia of ambiguous lineage, biphenotype, without CD34, TdT or TCR-rearrangement. 54 61
19687594 2009
43
New thrombopoietic growth factors. 54 61
19778863 2009
44
Clinical relevance of FLT3 gene abnormalities in Brazilian patients with infant leukemia. 54 61
19052976 2008
45
[Expression of SALL4 and BMI-1 mRNA in acute leukemia]. 54 61
19099625 2008
46
[Expression of erythropoietin receptor in leukemia cells and relation of erythropoietin level with leukemic anemia]. 54 61
19099624 2008
47
Chromosomal rearrangements leading to MLL gene fusions: clinical and biological aspects. 54 61
19074864 2008
48
Assessment of P-gp and MRP1 activities using MultiDrugQuant Assay Kit: a preliminary study of correlation between protein expressions and its functional activities in newly diagnosed acute leukaemia patients. 54 61
19291917 2008
49
Ceramide promotes apoptosis in chronic myelogenous leukemia-derived K562 cells by a mechanism involving caspase-8 and JNK. 54 61
18948750 2008
50
[Expression of cyclin A in childhood acute leukemia and its significance]. 54 61
19176011 2008

Variations for Acute Leukemia

Expression for Acute Leukemia

Search GEO for disease gene expression data for Acute Leukemia.

Pathways for Acute Leukemia

GO Terms for Acute Leukemia

Cellular components related to Acute Leukemia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 nucleoplasm GO:0005654 9.7 WT1 RUNX1 PAX5 MPO MLLT3 KMT2A
2 nuclear chromatin GO:0000790 9.63 RUNX1 PAX5 ETV6 DNTT CREBBP CEBPA
3 cytosol GO:0005829 9.44 WT1 STMN1 RUNX1 PAX5 MTHFR MLLT3

Biological processes related to Acute Leukemia according to GeneCards Suite gene sharing:

(show all 17)
# Name GO ID Score Top Affiliating Genes
1 cell differentiation GO:0030154 10.03 STMN1 PAX5 JAK2 FLT3 ETV6 ANPEP
2 negative regulation of transcription by RNA polymerase II GO:0000122 9.95 WT1 RUNX1 PAX5 ETV6 CREBBP CEBPA
3 transcription by RNA polymerase II GO:0006366 9.84 PAX5 MLLT3 KMT2A CEBPA
4 positive regulation of transcription, DNA-templated GO:0045893 9.8 WT1 RUNX1 MLLT3 KMT2A CREBBP CEBPA
5 positive regulation of transcription by RNA polymerase II GO:0045944 9.76 WT1 RUNX1 PAX5 KMT2A ETV6 CSF3
6 cytokine-mediated signaling pathway GO:0019221 9.65 KIT JAK2 FLT3 CSF3 CEBPA
7 hemopoiesis GO:0030097 9.61 RUNX1 KIT FLT3
8 regulation of transcription, DNA-templated GO:0006355 9.61 WT1 RUNX1 PAX5 MLLT3 KMT2A ETV6
9 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.58 KIT JAK2 FLT3
10 interleukin-6-mediated signaling pathway GO:0070102 9.57 JAK2 CEBPA
11 embryonic hemopoiesis GO:0035162 9.55 KMT2A KIT
12 hematopoietic stem cell proliferation GO:0071425 9.52 RUNX1 ETV6
13 regulation of B cell receptor signaling pathway GO:0050855 9.51 RUNX1 PAX5
14 regulation of myeloid cell differentiation GO:0045637 9.49 RUNX1 CREBBP
15 granulocyte differentiation GO:0030851 9.46 CSF3 CEBPA
16 myeloid progenitor cell differentiation GO:0002318 9.37 KIT FLT3
17 positive regulation of phosphatidylinositol 3-kinase signaling GO:0014068 8.92 KIT JAK2 FLT3 CSF3

Molecular functions related to Acute Leukemia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 transcription regulatory region DNA binding GO:0044212 9.56 WT1 RUNX1 KMT2A CEBPA
2 DNA-binding transcription activator activity, RNA polymerase II-specific GO:0001228 9.55 WT1 RUNX1 PAX5 ETV6 CEBPA
3 DNA-binding transcription factor activity, RNA polymerase II-specific GO:0000981 9.5 WT1 RUNX1 PAX5 MLLT3 KMT2A ETV6
4 DNA-binding transcription factor activity GO:0003700 9.17 WT1 RUNX1 PAX5 KMT2A ETV6 CEBPA

Sources for Acute Leukemia

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....